TY - JOUR
T1 - A low-glucose eating pattern is associated with improvements in glycemic variability among women at risk for postmenopausal breast cancer
T2 - an exploratory analysis
AU - Jospe, Michelle R.
AU - Liao, Yue
AU - Giles, Erin D.
AU - Hudson, Barry I.
AU - Slingerland, Joyce M.
AU - Schembre, Susan M.
N1 - Publisher Copyright:
Copyright © 2024 Jospe, Liao, Giles, Hudson, Slingerland and Schembre.
PY - 2024
Y1 - 2024
N2 - Background: High glycemic variability (GV) is a biomarker of cancer risk, even in the absence of diabetes. The emerging concept of chrononutrition suggests that modifying meal timing can favorably impact metabolic risk factors linked to diet-related chronic disease, including breast cancer. Here, we examined the potential of eating when glucose levels are near personalized fasting thresholds (low-glucose eating, LGE), a novel form of timed-eating, to reduce GV in women without diabetes, who are at risk for postmenopausal breast cancer. Methods: In this exploratory analysis of our 16-week weight loss randomized controlled trial, we included 17 non-Hispanic, white, postmenopausal women (average age = 60.7 ± 5.8 years, BMI = 34.5 ± 6.1 kg/m2, HbA1c = 5.7 ± 0.3%). Participants were those who, as part of the parent study, provided 3–7 days of blinded, continuous glucose monitoring data and image-assisted, timestamped food records at weeks 0 and 16. Pearson’s correlation and multivariate regression were used to assess associations between LGE and GV, controlling for concurrent weight changes. Results: Increases in LGE were associated with multiple unfavorable measures of GV including reductions in CGM glucose mean, CONGA, LI, J-Index, HBGI, ADDR, and time spent in a severe GV pattern (r = −0.81 to −0.49; ps < 0.044) and with increases in favorable measures of GV including M-value and LBGI (r = 0.59, 0.62; ps < 0.013). These associations remained significant after adjusting for weight changes. Conclusion: Low-glucose eating is associated with improvements in glycemic variability, independent of concurrent weight reductions, suggesting it may be beneficial for GV-related disease prevention. Further research in a larger, more diverse sample with poor metabolic health is warranted. Clinical trial registration: ClinicalTrials.gov, NCT03546972.
AB - Background: High glycemic variability (GV) is a biomarker of cancer risk, even in the absence of diabetes. The emerging concept of chrononutrition suggests that modifying meal timing can favorably impact metabolic risk factors linked to diet-related chronic disease, including breast cancer. Here, we examined the potential of eating when glucose levels are near personalized fasting thresholds (low-glucose eating, LGE), a novel form of timed-eating, to reduce GV in women without diabetes, who are at risk for postmenopausal breast cancer. Methods: In this exploratory analysis of our 16-week weight loss randomized controlled trial, we included 17 non-Hispanic, white, postmenopausal women (average age = 60.7 ± 5.8 years, BMI = 34.5 ± 6.1 kg/m2, HbA1c = 5.7 ± 0.3%). Participants were those who, as part of the parent study, provided 3–7 days of blinded, continuous glucose monitoring data and image-assisted, timestamped food records at weeks 0 and 16. Pearson’s correlation and multivariate regression were used to assess associations between LGE and GV, controlling for concurrent weight changes. Results: Increases in LGE were associated with multiple unfavorable measures of GV including reductions in CGM glucose mean, CONGA, LI, J-Index, HBGI, ADDR, and time spent in a severe GV pattern (r = −0.81 to −0.49; ps < 0.044) and with increases in favorable measures of GV including M-value and LBGI (r = 0.59, 0.62; ps < 0.013). These associations remained significant after adjusting for weight changes. Conclusion: Low-glucose eating is associated with improvements in glycemic variability, independent of concurrent weight reductions, suggesting it may be beneficial for GV-related disease prevention. Further research in a larger, more diverse sample with poor metabolic health is warranted. Clinical trial registration: ClinicalTrials.gov, NCT03546972.
KW - blood glucose self-monitoring
KW - continuous glucose monitoring
KW - food intake regulation
KW - glucose-guided eating
KW - glycemic control
UR - http://www.scopus.com/inward/record.url?scp=85191058081&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85191058081&partnerID=8YFLogxK
U2 - 10.3389/fnut.2024.1301427
DO - 10.3389/fnut.2024.1301427
M3 - Article
AN - SCOPUS:85191058081
SN - 2296-861X
VL - 11
JO - Frontiers in Nutrition
JF - Frontiers in Nutrition
M1 - 1301427
ER -